Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results
Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results
Nurix Therapeutics (NASDAQ:NRIX – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02), Fidelity Earnings reports. Nurix Therapeutics had a negative return on equity of 45.28% and a negative net margin of 399.14%.
紐裏克斯治療公司(納斯達克：NRIX-GET評級)週四發佈了季度收益數據。富達收益報告顯示，該公司本季度每股收益(EPS)為1.01美元，低於市場普遍預期的0.99美元和0.02美元。紐瑞克斯治療公司的淨資產回報率為負45.28%，淨利潤率為負399.14%。
NRIX stock opened at $17.71 on Friday. The company's 50-day moving average price is $10.99 and its 200 day moving average price is $15.41. Nurix Therapeutics has a 52 week low of $7.52 and a 52 week high of $37.42.
上週五，NRIX股價開盤報17.71美元。該公司的50日移動均線價格為10.99美元，200日移動均線價格為15.41美元。Nurix Treateutics的52周低點為7.52美元，52周高點為37.42美元。
Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its position in Nurix Therapeutics by 104.1% during the first quarter. Dimensional Fund Advisors LP now owns 237,525 shares of the company's stock worth $3,328,000 after acquiring an additional 121,167 shares during the last quarter. UBS Group AG raised its position in Nurix Therapeutics by 49.7% during the first quarter. UBS Group AG now owns 148,704 shares of the company's stock worth $2,083,000 after acquiring an additional 49,367 shares during the last quarter. Alyeska Investment Group L.P. raised its position in Nurix Therapeutics by 5.0% during the first quarter. Alyeska Investment Group L.P. now owns 120,750 shares of the company's stock worth $1,692,000 after acquiring an additional 5,750 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Nurix Therapeutics by 34.1% in the first quarter. JPMorgan Chase & Co. now owns 120,516 shares of the company's stock valued at $1,688,000 after buying an additional 30,664 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its position in shares of Nurix Therapeutics by 1,634.1% in the first quarter. Ensign Peak Advisors Inc now owns 84,797 shares of the company's stock valued at $1,188,000 after buying an additional 79,907 shares during the last quarter. Institutional investors own 89.94% of the company's stock.
機構投資者和對衝基金最近對他們在該業務中的頭寸進行了調整。Dimension Fund Advisors LP在第一季度將其在Nurix Treateutics的頭寸提高了104.1%。Dimension Fund Advisors LP在上個季度額外收購了121,167股後，現在擁有237,525股該公司股票，價值3,328,000美元。UBS Group AG在第一季度將其在Nurix Treeutics的頭寸提高了49.7%。瑞銀集團目前持有148,704股該公司股票，價值2,083,000美元，在上個季度增持了49,367股。Alyeska Investment Group L.P.在第一季度將其在Nurix Treeutics的頭寸提高了5.0%。Alyeska Investment Group L.P.現在持有120,750股該公司股票，價值1,692,000美元，在上個季度增持了5,750股。摩根大通在第一季度將其在Nurix Treateutics股票的持倉量提高了34.1%。摩根大通公司目前持有120,516股該公司股票，價值1,688,000美元，上一季度又購買了30,664股。最後，Ensign Peak Advisors Inc.在第一季度將其在Nurix Treateutics的股票頭寸提高了1634.1%。Ensign Peak Advisors Inc.在上個季度額外購買了79,907股後，現在擁有84,797股該公司股票，價值1,188,000美元。機構投資者持有該公司89.94%的股票。
About Nurix Therapeutics (Get Rating)
關於Nurix Treateutics(獲取評級)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Nurix治療公司是一家生物製藥公司，專注於治療癌症和免疫疾病的小分子療法的發現、開發和商業化。該公司開發了用於治療復發或難治性B細胞惡性腫瘤的口服布魯頓酪氨酸激酶(BTK)降解劑NX-2127；用於治療復發或難治性B細胞惡性腫瘤和自身免疫性疾病的口服生物可用BTK降解劑NX-5948；以及口服可用於免疫腫瘤學適應症的Casitas B細胞性淋巴瘤原癌基因B(CBL-B)抑制劑NX-1607。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- MarketBeat: Week in Review 7/4 – 7/8
- Levi Strauss Proves Resilient For Dividend Investors
- AT&T (NYSE:T) Is Its Cheaper Valuation Worth A Buy?
- Altria Group (NYSE MO): A Contentious High-Yield Dividend Stock
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 免費獲取StockNews.com關於Nurix治療的研究報告(NRIX)
- MarketBeat：回顧中的一週7/4-7/8
- 列維·施特勞斯被證明對股利投資者具有彈性
- 美國電話電報公司(紐約證券交易所代碼：T)較低的估值值得買入嗎？
- 奧馳亞集團：備受爭議的高收益股利股票
- 3種食品雜貨股可以幫助緩解通脹
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nurix治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nurix Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。